Monday 16 September 2019

12:00-12:15 


Opening
LOC President: Ulrike Köhl (Fraunhofer IZI, Leipzig) and
DG-GT President: Boris Fehse (University Hospital Hamburg-Eppendorf)

12:15-13:45


Session I: Pre-clinical development I
Michael Hudecek (University of Würzburg)
Hinrich Abken (Regensburg Center for Inverventional Immunology)
CARs, TRUCKs and beyond: the next generation of CAR T cells


13:45-14:00


Comfort break

14:00-15:30


Session II: Pre-clinical development II
Michael Bachmann (Helmholtz Center Dresden Rossendorf)

selected abstracts


15:30-16:00


Coffee break

16:00-17:30


Session III: Vector production and manufacturing
Klaus Kühlcke (BioNTech, Mainz)
Kai Pinkernell (Medigene, Planegg)
Ulrike Köhl (Fraunhofer IZI, Leipzig)

selected abstracts

17.30-18.00


DG-GT General Assembly


18:30-22:00


Networking Reception

 

Tuesday 17 September 2019

09:00-10:15


Session IV: Regulation
Cornelie Haag (Technical University Dresden)
Nina Worel (Medical University of Vienna)
Matthias Renner (Paul Ehrlich Institute)
Regulatory roundtable with regulatory professionals, clinicians and ethicists


10:15-10:45


Coffee break

10:45-12:45


Session V: Clinical studies I
John Maher (King's College London)
Pan-ErbB CAR T-cell immunotherapy of head and neck cancer: phase I clinical trial
Stephan Mielke (Karolinska Institute, Stockholm)
Hans Stauss (University College London)
Andrea Jarisch (University Hospital Frankfurt)


12:45-14:00


Lunch and poster session

14:00-14:30


Keynote: Ethics of CAR-T cells
Christiane Woopen (University of Cologne)

14:30-16:30


Session VI: Clinical studies II
Winfried Wels (Georg Speyer Haus, Frankfurt)
CAR-engineered NK cells: off-the-shelf therapeutics bridging innate and adaptive immunity
Christos Georgiades (University College London)
Chiara Bonini (San Raffaele Hospital, Milan)

Selected abstracts


17:00-17:30


Closing drinks